Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P81274
UPID:
GPSM2_HUMAN
Alternative names:
Mosaic protein LGN
Alternative UPACC:
P81274; Q5T1N8; Q6IBL7; Q8N0Z5
Background:
G-protein-signaling modulator 2, also known as Mosaic protein LGN, is pivotal in mitotic spindle pole organization through its interaction with NUMA1. It is essential for metaphase spindle orientation and plays a crucial role in asymmetric cell divisions. Additionally, it exhibits GDI activity towards G(i) alpha proteins, regulating their activity.
Therapeutic significance:
Linked to Chudley-McCullough syndrome, a neurologic disorder with early-onset sensorineural deafness and specific brain anomalies, understanding the role of G-protein-signaling modulator 2 could open doors to potential therapeutic strategies.